Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement
Authors:
Open Access
- 5 February 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (2) , e1921669
Abstract
Hypertrophic cardiomyopathy (HCM) and valvular aortic stenosis can both present with left ventricular outflow obstruction and hypertrophy. In patients with aortic stenosis and coexisting HCM undergoing transcatheter aortic valve replacement (TAVR), this can pose a management dilemma, as one condition can modulate the effects of the other. Indeed, there has been anecdotal concern that treating the aortic valve prior to treating outflow tract obstruction may result in higher mortality due to exacerbation of subvalvular obstruction. There are limited data on optimal management or outcomes of coexisting HCM and aortic stenosis in patients who undergo TAVR. We conducted a retrospective cohort study using the National Inpatient Sample to identify the association of known HCM with outcomes following TAVR.Keywords
This publication has 3 references indexed in Scilit:
- Undiagnosed hypertrophic obstructive cardiomyopathy during transcatheter aortic valve replacement: a case reportJournal of Medical Case Reports, 2018
- Combined Transcatheter Aortic Valve Replacement and Emergent Alcohol Septal AblationCirculation, 2013
- Suicide left ventricle following transcatheter aortic valve implantationCatheterization and Cardiovascular Interventions, 2010